ReviewBiochimica et biophysica acta. Reviews on cancer2021
Peptides that immunoactivate the tumor microenvironment.
Review in Biochimica et biophysica acta. Reviews on cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Small but mighty: Peptides as next-generation immunotargeting agents in gynecological cancers.Translational oncology · 2026Review
- The Dual Role of Natural Peptides in Cancer Therapy: Anticancer and Immunomodulatory Perspectives.Oncology research · 2026Review
- The Invertebrate-Derived Antimicrobial Peptide Cm-p5 Induces Cell Death and ROS Production in Melanoma Cells.Marine drugs · 2025Article
- Recent advances in biomimetic nanodelivery systems for cancer Immunotherapy.Materials today. Bio · 2025Review
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal transduction and targeted therapy · 2025Review
- Article
- Learning peptide properties with positive examples only.Digital discovery · 2024Article
- Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth.Cell death discovery · 2024Article
- (Nano)biotechnological approaches in the treatment of cervical cancer: integration of engineering and biology.Frontiers in immunology · 2024Review
- Potential of targeting signal-transducing adaptor protein-2 in cancer therapeutic applications.Exploration of targeted anti-tumor therapy · 2024Review
- Gel-forming therapeutic peptide exhibits sustained delivery and efficacy in a mouse model of triple-negative breast cancer.Peptides · 2023Article
- Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth.Research square · 2023Article
- Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.International journal of molecular sciences · 2023Review
- Development of a nitrogen-bound hydrophobic auxiliary: application to solid/hydrophobic-tag relay synthesis of calpinactam.Chemical science · 2023Article
- Glycomimetic Peptides as Therapeutic Tools.Pharmaceutics · 2023Review
- High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells.Cell death & disease · 2022Article
- Peptidomic Analysis on Mouse Lung Tissue Reveals AGDP as a Potential Bioactive Peptide against Pseudorabies Virus Infection.International journal of molecular sciences · 2022Article
- MicroRNA-497-5p Is Downregulated in Hepatocellular Carcinoma and Associated with Tumorigenesis and Poor Prognosis in Patients.International journal of genomics · 2021Article
- LncRNA FOXP4-AS1 Promotes Progression of Ewing Sarcoma and Is Associated With Immune Infiltrates.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cancer immunotherapy has achieved positive clinical outcomes and is revolutionizing cancer treatment. However, cancer immunotherapy has thus far failed to improve outcomes for most "cold tumors", which are characterized by low infiltration of immune cells and immunosuppressive tumor microenvironment. Enhancing the responsiveness of cold tumors to cancer immunotherapy by stimulating the components of the tumor microenvironment is a strategy pursued in the last decade. Currently, most of the agents used to modify the tumor microenvironment are small molecules or antibodies. Small molecules exhibit low affinity and specificity towards the target and antibodies have shortcomings such as poor tissue penetration and high production cost. Peptides may overcome these drawbacks and therefore are promising materials for immunomodulating agents. Here we systematically summarize the currently developed immunoactivating peptides and discuss the potential of peptide therapeutics in cancer immunology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.